Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Revenue (2016 - 2025)

Historic Revenue for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to $1.7 million.

  • Fate Therapeutics' Revenue fell 4336.37% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year decrease of 4692.5%. This contributed to the annual value of $13.6 million for FY2024, which is 7854.5% down from last year.
  • Latest data reveals that Fate Therapeutics reported Revenue of $1.7 million as of Q3 2025, which was down 4336.37% from $1.9 million recorded in Q2 2025.
  • Over the past 5 years, Fate Therapeutics' Revenue peaked at $59.0 million during Q1 2023, and registered a low of $933000.0 during Q2 2023.
  • In the last 5 years, Fate Therapeutics' Revenue had a median value of $6.8 million in 2024 and averaged $12.3 million.
  • Data for Fate Therapeutics' Revenue shows a peak YoY increase of 62583.07% (in 2024) and a maximum YoY decrease of 9673.62% (in 2024) over the last 5 years.
  • Quarter analysis of 5 years shows Fate Therapeutics' Revenue stood at $17.1 million in 2021, then skyrocketed by 159.86% to $44.4 million in 2022, then plummeted by 96.22% to $1.7 million in 2023, then increased by 10.98% to $1.9 million in 2024, then fell by 6.4% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $1.9 million for Q2 2025, and $1.6 million during Q1 2025.